29 July 2020 - Health Canada's approval of Brivlera provides paediatric epilepsy patients with a treatment option which can be initiated at a therapeutic dose from day one.

UCB Canada announced today that Health Canada has approved Brivlera (brivaracetam) as an adjunctive therapy in the management of partial-onset seizures in patients 4 years of age and older with epilepsy who are not satisfactorily controlled with conventional therapy.iii This approval provides clinicians with a child-friendly option to prescribe Brivlera to their paediatric patients as a tablet or oral solution, offering flexible administration options which are important considerations when treating children.

Brivlera has been approved in Canada for the treatment of epilepsy in adults (>18 years of age) since 2016.

Read UCB press release